Stocks News

LAST PRICE
54.8600
TODAY'S CHANGE (%)
Trending Up3.2400 (6.2766%)

Bid / Lots
---/ ---
Ask / Lots
---/ ---
Open / Previous Close
53.1300 / 51.6200
Day Range
Low 53.0000
High 59.0693
52 Week Range
Low 43.4200
High 91.1000
Volume
3,659,151
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: CRSP
  
  CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
  
  ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:00 p.m. ET.
Nov 6, 2024
- DJ Crispr Therapeutics Price Target Maintained With a $53.00/Share by RBC Capital, from 11:28AM ET on Wednesday Nov 06, 2024 by Dow Jones
  11:28AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: CRSP
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CRSP/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 11:28 ET (16:28 GMT)
- DJ Crispr Therapeutics Is Maintained at Equal-Weight by Barclays, from 9:29AM ET on Wednesday Nov 06, 2024 by Dow Jones
  9:29AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: CRSP
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CRSP/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 09:29 ET (14:29 GMT)
- DJ Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham, from 5:41AM ET on Wednesday Nov 06, 2024 by Dow Jones
  5:41AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: CRSP
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CRSP/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 06, 2024 05:41 ET (10:41 GMT)
Nov 5, 2024
- CRISPR Therapeutics' Q3 Net Loss Narrows, from 9:32AM ET on Tuesday Nov 05, 2024 by MT Newswires
  9:32AM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: CRSP
  09:32 AM EST, 11/05/2024 (MT Newswires) -- CRISPR Therapeutics (CRSP) reported a Q3 net loss Tuesday of $1.01 per diluted share, narrowing from a loss of $1.41 a year earlier. Analysts polled by Capital IQ expected a net loss of $1.38 per share. Rev...

Nov 9, 2024
- Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit, from 10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
  10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
  Companies Mentioned: RARE
Nov 8, 2024
- Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AXSM
Nov 7, 2024
- DJ Apellis Pharmaceuticals Is Maintained at Outperform by Baird, from 12:51PM ET on Thursday Nov 07, 2024 by Dow Jones
  12:51PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: APLS
- DJ Denali Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co., from 7:46AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:46AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: DNLI
Nov 6, 2024
- *DJ Denali Therapeutics 3Q Loss/Shr 63c >DNLI, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: DNLI
- Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: DNLI
- DJ Apellis Pharmaceuticals Is Maintained at Buy by Citigroup, from 2:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  2:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: APLS
- DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 1:06PM ET on Wednesday Nov 06, 2024 by Dow Jones
  1:06PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RARE
- DJ Apellis Pharmaceuticals Is Maintained at Buy by Goldman Sachs, from 12:18PM ET on Wednesday Nov 06, 2024 by Dow Jones
  12:18PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: APLS
- DJ Ultragenyx Pharma Price Target Maintained With a $77.00/Share by RBC Capital, from 12:11PM ET on Wednesday Nov 06, 2024 by Dow Jones
  12:11PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RARE

CRISPR Therapeutics AG
NASDAQ:CRSPUnited States

Search Criteria

Nov 7, 2024

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

DJ Crispr Therapeutics Price Target Maintained With a $53.00/Share by RBC Capital, from 11:28AM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Crispr Therapeutics Is Maintained at Equal-Weight by Barclays, from 9:29AM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham, from 5:41AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

CRISPR Therapeutics' Q3 Net Loss Narrows, from 9:32AM ET on Tuesday Nov 05, 2024 by MT Newswires

Peers Headlines

Nov 9, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit, from 10:30AM ET on Saturday Nov 09, 2024 by Dow Jones

Nov 8, 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

DJ Apellis Pharmaceuticals Is Maintained at Outperform by Baird, from 12:51PM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Denali Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co., from 7:46AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

*DJ Denali Therapeutics 3Q Loss/Shr 63c >DNLI, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Apellis Pharmaceuticals Is Maintained at Buy by Citigroup, from 2:01PM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity, from 1:06PM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Apellis Pharmaceuticals Is Maintained at Buy by Goldman Sachs, from 12:18PM ET on Wednesday Nov 06, 2024 by Dow Jones

DJ Ultragenyx Pharma Price Target Maintained With a $77.00/Share by RBC Capital, from 12:11PM ET on Wednesday Nov 06, 2024 by Dow Jones